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Objective: Resource utilization (RU) in the care of patients with critical limb ischemia (CLI) is not well quantified. We
present a cohort study to quantify in-hospital RU and analyze the role of tissue loss (TL), comorbidities, and vascular
graft-related events (GREs) in patients undergoing peripheral bypass for CLI.
Methods: A retrospective analysis of 1404 patients enrolled in a multicenter clinical trial (PREVENT III ) of vein bypass
grafting for CLI was performed with analysis of RU during the 1-year follow-up period. Univariate and multivariable
linear regressions were performed to determine RU predictors and outcomes.
Results: Compared with patients with rest pain, patients presenting with TL as the indication for bypass surgery had a
longer index length of stay (mean, 9.8 vs 6.2 days), more rehospitalizations (mean, 1.6 vs 1.2), and a longer cumulative
length of stay (mean, 27.7 vs 17.3 days; P < .0001 for all comparisons). Rehospitalizations over the ensuing year were
for additional procedures (37.5%), wound infection (14.6%), graft failure (10.7%), and other cardiovascular (10%) and
noncardiovascular (26%) reasons. Early GRE (stenosis>70%, thrombosis, revision, or major amputation within 30 days)
occurred in 162 (11.5%) patients, resulting in a longer index length of stay (mean, 11.8 vs 8.6 days; P  .0002) and
cumulative length of stay (mean, 25.9 vs 24.6 days; P  .0043), but no difference in the number of rehospitalizations
(mean, 1.6 vs 1.5 days; P  .3272). During the 1-year follow-up, 554 (39.5%) patients had GREs, and this resulted in
more rehospitalizations (mean, 2.1 vs 1.1; P < .0001) and a longer cumulative length of stay (mean, 28.2 vs 21.9 days;
P< .0001) compared with patients without GRE. Multivariable analysis demonstrated the highly positive association of
TL (hazard ratio [HR], 1.75) and early GRE (HR, 1.77) with the index length of stay, whereas comorbidities—namely,
dialysis dependency (HR, 1.31), nonsmoking status (HR, 1.29), hypertension (HR, 1.26), and increasing age
(HR, 1.01)—also had strong effects. The effect of TL andGRE on later RU (number of rehospitalizations and cumulative
length of stay) was present but less pronounced than patient comorbidities (namely, dialysis).
Conclusions:The stage of disease at presentation (TL vs rest pain) and the patency of the bypass graft (freedom fromGRE)
are critical determinants of RU over the first year after limb-salvage surgery. These effects predominate early (index length
of stay) and persist through 1 year. Patient-specific factors, particularly dialysis-dependent renal failure, are also critical
comorbidities affecting RU in these patients. ( J Vasc Surg 2006;44:971-6.)Considerable resources are required to diagnose, treat,
and follow up patients with chronic progressive critical limb
ischemia (CLI). These patients need limb salvage, arterial
intervention, and management of multiple medical comor-
bidities. Patient evaluation involves (1) diagnostic testing
to determine suitability for arterial revascularization and (2)
assessment of frequent comorbidities, such as coronary
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vage, especially in patients presenting with tissue loss (TL)
or foot infection, multiple procedures may be required, and
postoperative readmission for wound care is common. De-
spite best efforts, some patients may still experience limb
loss or develop procedure-related complications. Although
there are established general practice patterns in the treat-
ment of CLI, diagnostic, therapeutic, and follow-up deci-
sions vary among clinicians and institutions. Accordingly,
resource utilization (RU) will depend on the clinical deci-
sions and their outcomes.
Prior work on RU in vascular surgery has been descrip-
tive of one institution1,2 or has focused on the effect of
policy or protocol implementation.3 Several studies have
also examined utilization in specific vascular-related co-
horts limited to single institutions: dialysis patients4 and
diabetic foot ulcers.5 Studies using large databases such as
Medicare recipients have wider application, but they lack
depth in outcome analysis.6
This report details RU in a cohort study of 1404
patients who received infrainguinal lower extremity by-
passes for CLI in the PREVENT III trial. Measures of RU
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pitalizations (NOR), and cumulative length of stay (cLOS)
over the 1-year follow-up period. Our analysis examined
the influence of patient presentation, comorbidities, tech-
nical success, and mid-term graft patency on RU.
METHODS
Trial design. PREVENT III was amulticenter, double-
blinded, randomized, placebo-controlled trial of edifoli-
gide for the prevention of vein graft failure in patients
undergoing lower extremity bypass for the treatment of
CLI (gangrene, ischemic ulcer, or rest pain). Details of the
trial design have been previously reported.7 The trial was
sponsored by Corgentech Incorporated (South San Fran-
cisco, Calif ) and Bristol-Myers Squibb (Princeton, NJ).
Eighty-three sites in the United States and Canada ran-
domized 1404 patients aged more than 18 years with CLI
to receive either edifoligide or placebo during intraopera-
tive preparation of the vein graft. Exclusion criteria in-
cluded claudication as the indication for bypass, a nonau-
togenous component of the infrainguinal graft, or an in situ
vein graft configuration (treatment with edifoligide re-
quired ex vivo delivery to the vein graft). The primary trial
end point was reintervention for nontechnical index graft
failure or major amputation as a result of index graft failure
at 1 year.
Postoperative assessments included adverse event mon-
itoring during the first 30 days after bypass, intensive
ultrasound-based graft surveillance (1, 3, 6, and 12
months), and clinical follow-up with vascular examinations.
Rehospitalizations, additional procedures on the index
limb, and concomitant medications were recorded during
the 1-year study period. The primary reason for rehospital-
ization was determined by the treating surgeons according
to study-defined categories. Wound infections were defined
as having infection, necrosis, hematoma/hemorrhage, or
seroma/lymphocele at the surgical incision or harvest site.
Although the PREVENT III protocol recommended graft
revision for 70% stenosis, final decisions about graft revi-
sion, rehospitalizations, and other uses of resources were
left to the discretion of the treating surgeon.
Statistical analysis. Graft-related events (GREs) were
defined as thrombosis, stenosis of 70% or more (ultra-
sonography or angiography), revision, or major amputa-
tion.Early GREswere defined as those that occurred within
the first 30 days of the index bypass. Any GRE was defined
as GREs occurring within any time of the study, including
within the first 30 days. The iLOS was defined as the
number of postoperative days the patient was hospitalized
after the index operation; it was calculated by subtracting
the discharge date from the date of operation. The NOR
was defined as the number of inpatient readmissions in-
curred by the patient during the 1-year follow-up period.
The cLOSwas defined as the total number of inpatient days
incurred during the 1-year follow-up and includes the
iLOS.
Univariate comparisons of factors influencing RU out-
comes were performed with a Wilcoxon rank-sum orKruskal-Wallis test for categorical variables and a log-
transformed linear regression for continuous variables. The
following variableswere tested: age, sex, race, diabetes, dialysis
dependency, hyperlipidemia, hypertension, baseline aspirin
use, -blocker use, lipid-lowering agent use, smoking status,
treatment assignment (study drug), TL vs rest pain, and
occurrence of a GRE. Variables that demonstrated a potential
association (P  .20) were included in the multivariable
models. Multivariable analysis on iLOS and cLOS was
performed by using Cox proportional hazard models with
study termination (death or withdrawal) as the censoring
variable. NORmodeling was performed by using a Poisson
regression model to better fit the discrete NOR outcomes.
An  value of .05, corresponding to P  .05 and 95%
confidence intervals (CIs), was used as a criterion for statis-
tical significance. Analysis was performed by using SAS
version 9.1 (SAS Institute, Cary, NC).
RESULTS
The details of the demographics and comorbidities of
patients enrolled in the PREVENT III trial have been
previously reported.8,9 Pertinent demographic and surgical
data are summarized here. There were 1404 patients who
had lower extremity vein bypass as part of the PREVENT
III trial (897 men and 507 women; mean age, 69  12
years). The primary indication for surgery was ischemic rest
pain in 25%, nonhealing ulceration in 39%, and gangrene in
36%. The mean preoperative ankle-brachial index was
0.5  0.4. Sixty-four percent had diabetes, 73% were
smokers, 12% were on dialysis, and 28% had undergone a
previous infrainguinal bypass. During the 1-year follow-up
period, 222 patients (15.8%) died, 18 were lost to follow-
up, and 26 withdrew from the study. The most common
site of proximal anastomosis was the common femoral
artery (n  687; 49%), followed by the superficial femoral
artery (n 348; 25%), deep femoral artery (n 80; 5.7%),
and popliteal artery (n  247; 17.6%). The most common
site of distal anastomosis was the below-knee popliteal
artery (n  312; 22%), followed by the posterior tibial
artery (n  290; 21%), peroneal artery (n  239; 17%),
anterior tibial artery (n 219; 15.6%), pedal/plantar artery
(n  166; 11.8%), and above-knee popliteal artery (n 
145; 10%).
The results of PREVENT III have been reported9 and
are briefly summarized here only to provide context for the
RU analysis. Perioperative (30-day) mortality for the entire
cohort occurred in 38 patients (2.7%). Major perioperative
complications includedmyocardial infarction in 66 patients
(4.7%) and cerebrovascular events in 20 (1.4%). A total of
162 patients (11.5%) experienced an early GRE, including
occlusion of the index graft in 73 (5.2%) patients during the
first 30 days. At 1 year, primary graft patency was 61%,
secondary patency 80%, and limb salvage was 88% by
Kaplan-Meier estimates.
The mean iLOS was 8.8 days (median, 6 days; range,
1-117 days; Fig 1; Table I). Patients who initially presented
with TL (n  1046) had a longer iLOS (mean, 9.8 days;
median, 7 days; range, 1-117 days) than patients with rest
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days; P  .0001). Patients who experienced an early GRE
(n  162) had a longer iLOS (mean, 11.1 days; median,
7 days; range, 2-92 days) than those who had no early GRE
(n  1242; mean, 8.6 days; median, 6 days; range, 1-117
days; P  .0002). Patients who experienced any GRE
during the study had an iLOS (mean, 8.8 days; median,
6 days; range, 1-100 days) similar to the iLOS of those free
from GRE (mean, 8.9 days; median, 6 days; range, 1-117
days; P  .4573).
Overall, the mean NOR over the 1-year study period
was 1.5 (median, 1; range, 0-17); 436 patients had no
rehospitalizations, 426 had 1, 253 had 2, 121 had 3, and
168 had 4 (Fig 2). Patients who had TL at presentation
had a greater NOR (mean, 1.6; median, 1, range, 0-17)
than those with rest pain (mean, 1.2; median, 1; range, 0-7;
P  .0001). The occurrence of an early GRE had no
measurable effect on NOR (P .3272). However, patients
who experienced any GRE during the study had greater
NOR (mean, 2.1; median, 2.0; range, 0-11) than those
Fig 1. Frequency distribution of the index length of stay.
Table I. Resource utilization comparisons for TL
and GRE
Variable iLOS (d) NOR cLOS (d)
Total (N  1404) 8.8 (6) 1.5 (1) 24.8 (17)
Tissue loss (n  1046) 9.8 (7)* 1.6 (1)* 27.7 (21)*
Rest pain (n  353) 6.2 (5)* 1.2 (1)* 17.3 (9)*
Early GRE (n  162) 11.1 (8)* 1.6 (1) 25.9 (20)†
No early GRE (n  1242) 8.6 (6)* 1.5 (1) 24.6 (15)†
GRE during study (n  554) 8.8 (6) 2.1 (2)* 28.2 (20)*
No GRE during study
(n  867) 8.9 (6) 1.1 (1)* 21.9 (13)*
TL, Tissue loss; GRE, graft-related event; iLOS, index length of stay;NOR,
number of rehospitalizations; cLOS, cumulative length of stay.
Data are expressed as mean (median).
*P  .001 for intragroup comparisons.
†P  .05 for intragroup comparisons.without GRE (mean, 1.1; median, 1.0; range, 0-16;P .0001). The most common primary reasons for rehos-
pitalizations included additional non–graft-related proce-
dures on the index leg (25.6%), nonvascular issues (25.8%),
wound infections in the index leg (14.6%), and graft failure
(10.6%) (Table II).
The mean cLOS for the 1-year follow-up was 24.8 days
(median, 15.5 days; range, 1-365 days). Increased cLOS
was positively associated with TL (mean, 27.7 vs 17.3 days;
P .0001), the occurrence of an early GRE (mean, 25.9 vs
24.6 days; P  .0043), and GRE during the 1-year
follow-up period (mean, 28.2 vs 21.9 days; P  .0001).
Multivariable regression analysis showed that early
GRE (hazard ratio [HR], 1.77; 95% CI, 1.412-2.169; P
.0001) and TL (HR, 1.75; 95% CI, 1.412-2.169; P 
.0001) had the greatest effect on increasing iLOS, whereas
dialysis (HR, 1.31; 95% CI, 1.042-1.639; P  .0209),
nonsmoking status (HR, 1.291; 95% CI, 1.090-1.530; P
.0032), hypertension (HR, 1.26; 95% CI, 1.018-1.567;
P .0336), and increasing age (HR, 1.01; 95% CI, 1.000-
1.014; P  .0489) had less pronounced but significant
effects (Table III). Dialysis (relative risk, 1.64; 95% CI,
1.432-1.868; P  .0001), TL (relative risk, 1.30; 95% CI,
1.100-1.546; P  .0022), any GRE during the study
Fig 2. Frequency distribution of number of rehospitalizations in
1 year.
Table II. Reasons for hospital admission over a 1-year
follow-up period (N  2149)
Primary reason for readmission n %
Nonvascular medical 555 25.8%
Additional procedure in the index leg
(non–graft-related) 550 25.6%
Wound infection in index leg 313 14.6%
Nonvascular procedural 263 12.2%
Index graft failure 228 10.6%
New peripheral vascular disease 143 6.7%
Myocardial infarction 40 1.9%
Stroke 31 1.4%
Unknown 26 1.2%(relative risk, 1.30; 95% CI, 1.166-1.450; P .0001), and
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.0273) were associated with increasingNOR.Dialysis (HR,
1.96; 95% CI, 1.527-2.571; P  .0001), TL (HR, 1.61;
95% CI, 1.297-2.020), any GRE during the study (HR,
1.56; 95%CI, 1.326-1.838; P .0147), and nonwhite race
(HR, 1.12; 95% CI, 1.036-1.838; P .0049) were associ-
ated with greater cLOS. Treatment assignment to edifoli-
gide or placebo was not associated with increased RU in
univariate or multivariable analysis.
DISCUSSION
The course of patients who undergo lower extremity
bypass can be affected by many factors. Accordingly, the
resources used in caring for these patients can vary greatly.
This study examined the resources used for CLI patients
who received lower extremity bypass at 83 institutions. Our
findings of a mean iLOS of 8.8 days for lower extremity
bypass are consistent with prior findings from other au-
thors.10,11 To our knowledge, only one study from the
Veterans Administration has looked at RU and clinical
outcomes in peripheral vascular surgery across many insti-
tutions in great detail. Those authors found that age,
presence of complications, patient complexity, illness sever-
ity, and acute arterial thromboembolism were increasingly
and independently associated with greater in-hospital mor-
tality.12 However, outcomes were limited to in-hospital
findings and did not include any long-term follow-up.
Although most prior published studies focus on length of
stay after the index bypass, no prior study has examined the
resources used in the subsequent care of patients after
limb-salvage surgery.
For patients with CLI, TL is one easily identifiable
measure of disease severity. In our study, patients who
Table III. Significant factors in multivariable analysis for
RU outcomes
Outcome Factor HR 95% CI P value
ILOS Early GRE 1.77 1.350-2.315 .0001
Tissue loss 1.75 1.412-2.169 .0001
Dialysis 1.31 1.042-1.639 .0209
Nonsmoking status 1.29 1.090-1.530 .0032
Hypertension 1.26 1.018-1.567 .0032
Increasing age 1.01 1.000-1.014 .0489
RR
NOR Dialysis 1.64 1.432-1.868 .0001
Tissue loss 1.30 1.100-1.546 .0022
GRE 1.30 1.166-1.450 .0001
Hypertension 1.21 1.021-1.425 .0273
HR
cLOS Dialysis 1.96 1.527-2.571 .0001
Tissue loss 1.61 1.297-2.020 .0001
GRE 1.56 1.326-1.838 .0001
Nonwhite race 1.12 1.036-1.838 .0049
RU, Resource utilization; HR, hazard ratio; CI, confidence interval; iLOS,
index length of stay; GRE, graft-related event;NOR, number of rehospital-
izations; cLOS, cumulative length of stay; RR, risk ratio.presented with TL experienced a greater iLOS, NOR, andcLOS compared with patients with rest pain. TL patients
were rehospitalized for additional non–graft-related proce-
dures in the leg. Early GRE also was highly associated with
greater iLOS, although an effect on subsequent NOR was
not seen. The association of early GRE with cLOS is due in
large part to the differences in iLOS. We also found that
patients who had early GRE but were successfully treated
and maintained patency during the study period tended to
have lower cLOS than patients whose grafts were not
successfully salvaged, although this was not statistically
significant. Not surprisingly, patients who experienced a
GRE at any time during the study had a greater NOR and
longer cLOS than patients who were free from any GRE.
Multivariable analysis also demonstrated the highly
positive association of TL and GRE with iLOS, although
comorbidities (namely, increasing age, hypertension, dial-
ysis dependency, and nonsmoking status) also had positive
effects. The effect of TL and GRE on later RU (beyond the
index hospitalization) was less pronounced than patient
factors and comorbidities, particularly dialysis-dependent
renal failure. In essence, vascular disease presentation (as
represented by TL) and GRE have early RU effects that
persist but taper in later periods, whereas patient comor-
bidities have smaller early effects that become more prom-
inent in the long-term.
One limitation in this study is patient selection bias. All
patients in the study cohort were participants in a clinical
trial. However, the entry criteria for PREVENT III were
broadly inclusive7 and, hence, are largely reflective of the
general population of CLI patients undergoing surgical
revascularization. The measures of RU in this study were
chosen because they reflected utilization not required by
the trial protocol. The iLOS, NOR, and cLOS were left to
the discretion of the patient’s surgeon or other relevant
medical health care providers in the case of nonsurgical
admissions. Arguably, patients in trials may be subjected to
closer scrutiny and follow-up than other patients, thus
resulting in higher RU. Although this is a potential source
of bias, concomitant financial and clinical factors may still
play a large role in negating that bias. Furthermore, the bias
is likely to be less for nonvascular readmissions because
those admitting physicians are presumably more removed
from the study. The study surgeons and their institutions
were also selected to participate in the trial because of their
prior interest and experience in caring for CLI patients.
Thus, the conclusions from this study may not be directly
applicable to institutions that differ in practice characteris-
tics or case volumes.
Although most of the positive factors in the multivari-
able analysis associated with increased RU are clinically
intuitive, we do not have a definitive explanation for the
isolated association of nonsmoking status with increased
iLOS and nonwhite race with cLOS. We speculate that
nonsmokers (while controlling for diabetes and other re-
lated variables) who develop CLI have an increased burden
of cardiovascular disease that is not yet well quantified.
Likewise, nonwhite race may be associated with socioeco-
nomic factors that result in increased cLOS.
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PREVENT III study was not designed to capture all the
resources that patients incur in the care of their CLI.
Length of stay and NOR are proxies for RU that are easy to
understand and generalize. We have not performed cost
accounting for actual materials, equipment, and profes-
sional time used during these hospitalizations. Those data
are not available from the PREVENT III study. We have
also not accounted for rehabilitation resources, visiting
nurses, family contributions, loss of labor by the patient,
and many other direct and indirect resources in preparation
for revascularization and during the year afterward. Such
precise accounting is beyond the scope of this study, al-
though it is the authors’ future intent to explore these areas
by using financial and economic tools.
In summary, this study found that TL was highly
associated with increased RU in early and later time peri-
ods. The effect of early GRE was significant in early RU but
diminished in later time periods. GRE in later periods
incurred greater RU in subsequent time periods. Several
patient demographics and comorbidities were also associ-
ated with RU, including dialysis-dependent renal failure,
older age, hypertension, and nonwhite race. Our findings
may have implications for patient care and health care
policy. Prevention of TL through patient and physician
education, better foot care, or earlier detection of periph-
eral arterial disease may decrease RU. Similarly, early GREs
are commonly attributed to technical problems, and thus
efforts to reduce such events through training or process
improvements may also reduce RU. Mid-term graft failure
is common and also incurs significant RU; hence, the
development of novel strategies to reduce the frequency of
vein graft disease would have important benefits to the
health care system. Finally, our findings further under-
score the significant care needs of CLI patients beyond
their revascularization procedure, and current resource
allocations for this patient population may need to be
re-examined.
CONCLUSIONS
Several patient-specific factors, including dialysis-
dependent renal failure, older age, hypertension, and non-
white race, have important effects on RU during the first
postoperative year. Stage of disease at presentation (TL)
and sustained patency of the bypass graft (freedom from
GRE) are also critical determinants of RU in limb salvage
surgery. These effects predominate early (iLOS) and persist
through 1 year.
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The authors are to be congratulated on the foresight to
include measures of resource utilization in a prospective, random-
ized, multicenter clinical trial. The authors tracked the initial, or
index, length of stay, the number of rehospitalizations, and theaha, Neb
for critical limb ischemia. Tissue loss and graft-related events were
associated with greater resource utilization. Among comorbidities
and patient demographics, dialysis and hypertension had an effect
on both an early and cumulative use of resources, whereas non-
white race had an effect on cumulative length of stay.
